The Polsinelli Intellectual Property practice is a cross-functional group of attorneys organized to service all our client’s IP needs in a variety of industries. Our attorneys handle the most complex issues facing technology and high tech companies, bioscience and life sciences companies, animal science, medical device, pharmaceutical, chemical, software and business methods, data, privacy, health care IT, and any of a variety of other high tech industries.
In 2016 we became
one of the largest IP practices in the nation, with nearly 120 attorneys, patent agents and scientists dedicated to helping our clients solve their most complex issues related to the establishment and protection of their intellectual property. Ranked by Chambers USA
in (Intellectual Property) - 2016.
Our specific areas of focus include:
Our attorneys counsel Fortune 500 companies, mid-size public and private companies, start-ups, universities and not-for-profit research institutes on the versatile challenges these various clients face. We partner with our clients to ensure their ideas are adequately protected. Additionally, we gain a comprehensive understanding of our clients’ business so that our IP services work in conjunction with their business focus, ensuring the best possible outcome.
We assist our clients in developing intellectual property strategies, launching websites, raising capital, acquiring and selling technologies and companies, and developing strategic partnerships. We review and prepare a wide range of technology, vendor, and licensing agreements. We protect our clients’ assets through trademarks, copyrights, patents, licensing agreements, privacy policies, litigation, technology development agreements, and trade secret protection.
Our IP attorneys are supported by a team of Patent Agents and Scientists with impressive education including Ph.D.’s in Pharmacology, Molecular Microbiology and Integrative Biology, and work experience including a faculty position in a university’s Department of Biology, a consultant for pharmaceutical and biotechnology companies and a position at the National Institute of Standards and Technology.